Profil du fabricant
Bausch & Lomb Incorporated
Société pharmaceutique4 produits suivis
4
produits suivis
73 260
total des notifications
23
rappels enregistrés
47,8%
graves au total
Produits
affichage de 4 sur 4
| Produit | Approuvé | Notifications ↓ | Signal principal | Rappels |
|---|---|---|---|---|
| 2001 | 27 882 | augmentation de la pression intraoculaire | 9 | |
| 2001 | 27 882 | augmentation de la pression intraoculaire | 10 | |
| 2016 | 16 017 | Réaction au site d'instillation | 4 | |
| — | 1 479 | Vascularopathie choroïdienne polypoïde | 0 |
Historique des rappels · 14 enregistrés
| Date | Classe | Motif | Fabricant |
|---|---|---|---|
| 5 mars 2026 | II | Lack of Assurance of Sterility | Apotex Corp. |
| 5 sept. 2025 | II | Lack of Assurance of Sterility; atypical weight loss due to improper bottle sealing leading to potential sterility concerns | Apotex Corp. |
| 28 mai 2025 | II | Lack of Assurance of Sterility | Apotex Corp. |
| 1 mars 2023 | II | Lack of sterility assurance: Cracks have developed in some of the units caps of Brimonidine tartrate ophthalmic solution bottles. There is a possibility the broken cap may impact sterility. | Apotex Corp. |
| 10 mai 2022 | III | Failed Impurities/Degradation Specifications. | Novartis Pharmaceuticals Corporation |
| 10 mai 2022 | III | Failed Impurities/Degradation Specifications. | Novartis Pharmaceuticals Corporation |
| 10 mai 2022 | III | Failed Impurities/Degradation Specifications. | Novartis Pharmaceuticals Corporation |
| 10 mai 2022 | III | Failed Impurities/Degradation Specifications. | Novartis Pharmaceuticals Corporation |
| 4 juin 2020 | III | Failed Impurities/Degradation Specification: There is a slow leaching process from the product label on the bottle which may impact the product over the shelf life. | SOMERSET THERAPEUTICS LLC |
| 4 juin 2020 | III | Failed Impurities/Degradation Specification: There is a slow leaching process from the product label on the bottle which may impact the product over the shelf life. | SOMERSET THERAPEUTICS LLC |
| 4 juin 2020 | III | Failed Impurities/Degradation Specification: There is a slow leaching process from the product label on the bottle which may impact the product over the shelf life. | SOMERSET THERAPEUTICS LLC |
| 19 mars 2019 | II | cGMP Deviations | Allergan Sales, LLC |
| 19 oct. 2017 | III | Failed Impurities/Degradation Specifications. | Allergan Sales, LLC |
| 23 juin 2017 | II | Incorrect/Undeclared Excipient; non-pharmaceutical grade PEG 40 Castor Oil was used due to a mislabeling by the supplier | ImprimisRx CA, Inc., dba ImprimisRx |
Classe I = probabilité raisonnable de préjudice grave · Classe II = temporaire ou réversible · Classe III = peu susceptible de causer un préjudice.
Statut d'enregistrement
Certains produits de Bausch & Lomb Incorporated ne sont pas enregistrés auprès de la FDA pour un usage humain. Pour les substances non enregistrées (peptides, SARMs sans enregistrement humain), aucun fournisseur légitime à usage humain n'existe. L'absence de filière d'approvisionnement est l'information de sécurité.